Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ibeol (EPO) 36,000 IU vs 40,000 IU for chemotherapy-related anemia in solid tumors
ChiCTR2300067378Phase 4Not yet recruiting
- Sponsor
- Liaoning Province Cancer Hospital
- Start
- Oct 2022
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of epoetin alfa in chemotherapy-induced anaemia (CIA) and Non-hematologic malignancy (2 arms), sponsored by Liaoning Province Cancer Hospital. Primary endpoint: Hemoglobin level. Planned start Oct 2022; status: not yet recruiting.
02
Drugs
epoetin alfa
03
Conditions
chemotherapy-induced anaemia (CIA)Non-hematologic malignancy
Beyond the preview
Go deeper on ChiCTR2300067378.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300067378.